• +1-646-491-9876
    • +91-20-67278686

    Search

    Chlamydia Infections - Pipeline Review, H1 2017

    Chlamydia Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001767480
    • Category Pharmaceuticals
    • No. of Pages 66
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Chlamydia Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H1 2017, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

    Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

    Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Chlamydia Infections - Overview
    Chlamydia Infections - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Chlamydia Infections - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Chlamydia Infections - Companies Involved in Therapeutics Development
    Abera Bioscience AB
    Evofem Inc
    Lead Discovery Center GmbH
    Merck & Co Inc
    NanoBio Corp
    Prokarium Ltd
    QureTech Bio AB
    SATT IDF Innov SAS
    Selecta Biosciences Inc
    SIGA Technologies Inc
    Vault Pharma Inc
    Chlamydia Infections - Drug Profiles
    Ab-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acALY-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Amphora - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia trachomatis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia trachomatis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Chlamydia Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-669 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPI-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chlamydia Infections - Dormant Projects
    Chlamydia Infections - Product Development Milestones
    Featured News & Press Releases
    Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
    Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
    Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
    Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
    Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Chlamydia Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2017
    Chlamydia Infections - Pipeline by Evofem Inc, H1 2017
    Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H1 2017
    Chlamydia Infections - Pipeline by Merck & Co Inc, H1 2017
    Chlamydia Infections - Pipeline by NanoBio Corp, H1 2017
    Chlamydia Infections - Pipeline by Prokarium Ltd, H1 2017
    Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2017
    Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H1 2017
    Chlamydia Infections - Pipeline by Selecta Biosciences Inc, H1 2017
    Chlamydia Infections - Pipeline by SIGA Technologies Inc, H1 2017
    Chlamydia Infections - Pipeline by Vault Pharma Inc, H1 2017
    Chlamydia Infections - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Chlamydia Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Abera Bioscience AB
    Evofem Inc
    Lead Discovery Center GmbH
    Merck & Co Inc
    NanoBio Corp
    Prokarium Ltd
    QureTech Bio AB
    SATT IDF Innov SAS
    Selecta Biosciences Inc
    SIGA Technologies Inc
    Vault Pharma Inc

    Request for Sample

    Report Url http://www.reportsweb.com//chlamydia-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chlamydia-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chlamydia-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments